₹103 per tablet and will be available as a 200 mg tablet at a maximum retail price of Rs3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir approved medication in India for the treatment of covid-19.However, analysts are not convinced that the drug will turnaround Glenmark’s business prospects and feel that the drug launch is unlikely to support the robust rally in shares. “It is merely a flu medicine and meant to cure mild to moderate covid-19 patients so may not necessarily be a game changer for treating the disease completely.
They could be probably treated by other flu medicines too, so FabiFlu does not hold any edge," said an analyst.In this year so far, Glenmark shares have risen over.